• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Rigel Pharmaceuticals Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket

    3/8/23 7:57:28 AM ET
    $ADIL
    $AUD
    $BNOX
    $EFOI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Broadcasting
    Consumer Discretionary
    Get the next $ADIL alert in real time by email

    Gainers

    • Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) rose 51.1% to $2.66 in pre-market trading after the company disclosed topline results from single and multiple ascending dose parts of Phase 1 study of oral DYRK1A inhibitor FRTX-02.
    • Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rose 30.6% to $1.92 in pre-market trading after posting better-than-expected Q4 results.
    • ObsEva SA (NASDAQ:OBSV) shares rose 27.5% to $0.1785 in pre-market trading after dropping 30% on Tuesday.
    • Zymeworks Inc. (NASDAQ:ZYME) shares rose 18.8% to $9.46 in pre-market trading following strong quarterly sales.
    • Maxeon Solar Technologies, Ltd. (NASDAQ:MAXN) rose 15.7% to $21.72 in pre-market trading following better-than-expected Q4 sales.
    • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) rose 15.4% to $0.2345 in pre-market trading after gaining around 17% on Tuesday.
    • WeWork Inc. (NYSE:WE) shares rose 11.4% to $1.27 in pre-market trading following a report suggesting the company is in talks to restructure its outstanding debt and raise additional cash.
    • Meten Holding Group Ltd. (NASDAQ:METX) rose 11.3% to $0.28 in pre-market trading.
    • Mesoblast Limited (NASDAQ:MESO) rose 10.9% to $3.36 in pre-market trading after the FDA accepted the company’s resubmission of the Biologic License Application for Remestemcel-L in children with steroid-refractory acute graft versus host disease as a complete response and sets goal date of Aug. 2, 2023.
    • AIM ImmunoTech Inc. (NASDAQ:AIM) rose 8.8% to $0.5550 in pre-market trading after declining over 3% on Tuesday.

    Losers

    • Troika Media Group, Inc. (NASDAQ:TRKA) fell 39.9% to $0.3367 in pre-market. Troika Media Group shares dropped around 27% on Tuesday after the company reported 1H financial results.
    • Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) fell 16.4% to $0.3701 in pre-market trading. Adial shares gained over 5% on Tuesday after the company provided an update on its regulatory strategy for AD04. Adial will pursue paths towards US and Europe approvals and said market research suggests pricing could be more than double prior assumptions.
    • Mercurity Fintech Holding Inc. (NASDAQ:MFH) shares dropped 15.5% to $1.09 in pre-market trading after jumping over 43% on Tuesday.
    • Appreciate Holdings, Inc. (NASDAQ:SFR) fell 13% to $2.61 in pre-market trading.
    • Virax Biolabs Group Limited (NASDAQ:VRAX) shares fell 12.4% to $1.06 in pre-market trading. Virax Biolabs shares gained 83% on Tuesday after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the European market..
    • Bionomics Limited (NASDAQ:BNOX) fell 12% to $3.81 in pre-market trading after surging 20% on Tuesday.
    • Audacy, Inc. (NYSE:AUD) shares fell 11.2% to $0.15 in pre-market trading. Audacy is expected to report its 2022 fourth quarter financial results on Wednesday, March 15, 2023.
    • Siyata Mobile Inc. (NASDAQ:SYTA) fell 9.7% to $0.2346 in pre-market trading after jumping over 32% on Tuesday.
    • SoundHound AI, Inc. (NASDAQ:SOUN) fell 8.7% to $3.04 in pre-market trading after the company reported fourth-quarter financial results and issued solid guidance.
    • Energy Focus, Inc. (NASDAQ:EFOI) fell 8.6% to $0.6110 in pre-market trading after gaining more than 28% on Tuesday.

    Now Read This: Top 5 Tech And Telecom Stocks Which You'll Regret Missing In Q1 2023

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $AUD
    $BNOX
    $EFOI

    CompanyDatePrice TargetRatingAnalyst
    Zymeworks Inc.
    $ZYME
    12/12/2025$33.00Equal Weight → Overweight
    Wells Fargo
    SoundHound AI Inc
    $SOUN
    12/12/2025$15.00Neutral → Overweight
    Cantor Fitzgerald
    Zymeworks Inc.
    $ZYME
    12/3/2025$32.00Mkt Outperform
    Citizens JMP
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    Rigel Pharmaceuticals Inc.
    $RIGL
    11/5/2025$42.00Hold → Buy
    Jefferies
    Zymeworks Inc.
    $ZYME
    10/24/2025$15.00Equal Weight
    Wells Fargo
    Zymeworks Inc.
    $ZYME
    10/14/2025$26.00Neutral → Buy
    H.C. Wainwright
    Zymeworks Inc.
    $ZYME
    10/10/2025$30.00Buy
    B. Riley Securities
    More analyst ratings

    $ADIL
    $AUD
    $BNOX
    $EFOI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zymeworks upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Zymeworks from Equal Weight to Overweight and set a new price target of $33.00

    12/12/25 8:37:46 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SoundHound AI upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded SoundHound AI from Neutral to Overweight and set a new price target of $15.00

    12/12/25 8:37:36 AM ET
    $SOUN
    Computer Software: Prepackaged Software
    Technology

    Citizens JMP initiated coverage on Zymeworks with a new price target

    Citizens JMP initiated coverage of Zymeworks with a rating of Mkt Outperform and set a new price target of $32.00

    12/3/25 8:41:52 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $AUD
    $BNOX
    $EFOI
    SEC Filings

    View All

    SEC Form 144 filed by Zymeworks Inc.

    144 - Zymeworks Inc. (0001937653) (Subject)

    3/6/26 9:00:02 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - AIM ImmunoTech Inc. (0000946644) (Filer)

    3/6/26 5:15:32 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adial Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

    3/6/26 8:15:35 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $AUD
    $BNOX
    $EFOI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIM ImmunoTech Announces Closing of its Rights Offering

    OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today the closing of its previously announced rights offering (the "Rights Offering"). The Rights Offering resulted in total subscriptions of approximately $1.8 million. Each right entitled the holder to purchase one unit ("Unit"), at a subscription price of $1,000 per Unit, consisting of one share of the Company's Series G Convertible Preferred Stock

    3/6/26 7:00:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

    GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2025 fiscal year ended December 31, 2025. Key Highlights: Regulatory Progress: Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04's pharmacologic profile and regulatory strategy.Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company's proposed in vitro bri

    3/6/26 8:00:00 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million

    OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced the preliminary results of its previously announced rights offering (the "Rights Offering") which expired at 5:00 p.m., Eastern Time, on March 3, 2026. The Company estimates that the Rights Offering will result in total subscriptions of approximately $1.8 million. The results of the Rights Offering are preliminary and subject to change pending fi

    3/4/26 9:00:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADIL
    $AUD
    $BNOX
    $EFOI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider See Tiffany Roslyn claimed ownership of 103,098 shares (SEC Form 3)

    3 - Maxeon Solar Technologies, Ltd. (0001796898) (Issuer)

    3/11/26 7:01:59 AM ET
    $MAXN
    Semiconductors
    Technology

    SEC Form 4 filed by AIM ImmunoTech Inc.

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    3/10/26 5:56:40 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by AIM ImmunoTech Inc.

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    3/10/26 5:56:37 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADIL
    $AUD
    $BNOX
    $EFOI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Huang Chiao Chieh bought $600,001 worth of shares (262,009 units at $2.29), increasing direct ownership by 23% to 1,421,219 units (SEC Form 4)

    4 - ENERGY FOCUS, INC/DE (0000924168) (Issuer)

    12/31/25 9:21:21 AM ET
    $EFOI
    Building Products
    Consumer Discretionary

    Chief Executive Officer Huang Chiao Chieh bought $500,000 worth of shares (264,550 units at $1.89), increasing direct ownership by 30% to 1,159,210 units (SEC Form 4)

    4 - ENERGY FOCUS, INC/DE (0000924168) (Issuer)

    8/19/25 6:04:55 AM ET
    $EFOI
    Building Products
    Consumer Discretionary

    Chief Executive Officer Huang Chiao Chieh bought $400,000 worth of shares (214,124 units at $1.87), increasing direct ownership by 31% to 894,660 units (SEC Form 4)

    4 - ENERGY FOCUS, INC/DE (0000924168) (Issuer)

    6/23/25 7:07:01 AM ET
    $EFOI
    Building Products
    Consumer Discretionary

    $ADIL
    $AUD
    $BNOX
    $EFOI
    Financials

    Live finance-specific insights

    View All

    Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 millionGenerated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefitEnrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and select the recommended Phase 2 dose for future c

    3/3/26 4:01:00 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potential launch in 2H 2026Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the U.S., Europe, Japan, and ChinaAdditional clinical data for pasritamig in prostate cancer presented at ASCO-GU in February 2026 by Johnson & Johnson Innovative Medicine (J&J)$62.5 million utilized for share repurchases as of March 2, 2026 under the current authorized share repurchase program$250.0 million non-recourse royalty-backed

    3/2/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SoundHound AI Reports Record Annual Revenue of $169 Million, Up Nearly 100%, Forecasts Strong Growth

    SANTA CLARA, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SoundHound AI, Inc. (NASDAQ:SOUN), a global leader in voice and conversational AI, today reported its financial results for the fourth quarter and full year 2025. "As traditional software faces massive AI disruption, businesses are looking to partner with AI natives that can help them achieve success in a new era. This is creating strong tailwinds for SoundHound," said Keyvan Mohajer, CEO and Co-Founder of SoundHound AI. "Our results speak for themselves. All key profit metrics were up and in the last quarter we closed a record number of customer deals as we capitalized on the surge in demand for enterprise-grade AI." Financial Hig

    2/26/26 4:06:00 PM ET
    $SOUN
    Computer Software: Prepackaged Software
    Technology

    $ADIL
    $AUD
    $BNOX
    $EFOI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Maxeon Solar Technologies Ltd.

    SC 13D/A - Maxeon Solar Technologies, Ltd. (0001796898) (Subject)

    11/26/24 8:54:35 PM ET
    $MAXN
    Semiconductors
    Technology

    $ADIL
    $AUD
    $BNOX
    $EFOI
    Leadership Updates

    Live Leadership Updates

    View All

    Rigel Appoints Michael P. Miller to the Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has more than four decades of experience in commercial and leadership roles in the biotechnology and pharmaceutical industries. "Mike has a strong track record of commercial excellence, and we're delighted to have him join our Board," said Raul Rodriguez, Rigel's president and CEO. "His extensive expertise in commercial execution and leadership will provide valuable insights as we execute on our transformational strategic plan, particularly our objectives of growing our current portfolio of medicines

    2/3/26 8:05:00 AM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

    VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer. Mr. Platshon will report directly to Zymeworks' Chair and Chief Executive Officer, Kenneth Galbraith, and work closely with him to manage expected future cash flows from Ziihera® (zanidatamab-hrii) and other healthcare assets and licensed product candidates, such as pasritamig, which is being advanced to Phase 3 registration studies by Johnson & Johnson Innovati

    11/18/25 1:01:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

    VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer. In this role, Dr. Schayowitz will report directly to Zymeworks' Chair & Chief Executive Officer, Kenneth Galbraith, and work closely with the Zymeworks R&D and Business Development teams to advance the Company's broad portfolio of nominated product candidates, while also

    10/9/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care